Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TALL 104

X
Drug Profile

TALL 104

Alternative Names: ABIO-05/01; ABIO-0501; Human MHC non-restricted cytotoxic T-cell line - Galileo Research; TALL-104

Latest Information Update: 26 May 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Wistar Institute
  • Developer Abiogen Pharma; Galileo Research; University of Texas M. D. Anderson Cancer Center
  • Class Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Cell death stimulants; Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Ovarian cancer
  • No development reported Peritoneal cancer
  • Discontinued Chronic myeloid leukaemia

Most Recent Events

  • 14 Apr 2023 Pharmacodynamics data from a preclinical trial in Cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
  • 19 Feb 2021 TALL 104 is still in phase II trial for Ovarian cancer (Late-stage disease, Metastatic disease) in Italy (Intraperitoneal) (EudraCT2013-001005-82)
  • 29 Jul 2015 No recent reports on development identified - Phase-I/II for Peritoneal cancer in Italy (IV & Intraperitoneal)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top